Grifols has seen a long share price slide in recent years, which naturally puts the focus on one question for investors who still follow the stock. Is the current price tag properly supported by the earnings the business is generating today.
-
Over the past 5 years the share price has fallen 54%, which makes the current valuation story hinge on whether the market has already absorbed weaker sentiment into the earnings multiple.
-
The group's ability to turn its plasma based operations into reliable profit and cash flow can shape how much investors are willing to pay for each euro of earnings, especially if margins stabilize or efficiency efforts start to stick.
-
The analysts covering Grifols have run their own numbers. See what analysts think Grifols's shares could be worth .
The stock's next move may depend on whether Grifols' current earnings can credibly justify the valuation investors are placing on the business today.
If you are weighing whether Grifols' earnings multiple still makes sense after a 54% share price decline over 5 years, it can help to compare it with other 182 high quality undervalued stocks
Does Grifols Look Undervalued on Earnings?
The P/E ratio suits Grifols because earnings are a key focus for a mature plasma and biotech operator. On this measure, the stock trades on about 14.4x earnings, which is well below the broader biotech sector at roughly 25.5x and also under the peer group average near 23.8x. For a reader, that means the market is currently paying fewer euros for each euro of Grifols' profit than for many comparable healthcare companies.
The fair value framework that links Grifols' multiple to its own mix of growth, profitability, size and risk suggests a higher P/E would be typical for this business profile. As a result, the current 14.4x level screens as undervalued against that yardstick. That gap indicates sentiment around the shares is more cautious than what the model implies for a firm with these earnings characteristics, which is the trade off to weigh. Explore the numbers behind Grifols's P/E valuation .
The Grifols Narrative: What Would Justify Today's Price?
Grifols' Simply Wall St Narratives pick up where that P/E puzzle leaves off and explain which combinations of future growth, margins and earnings would need to occur for the stock to be worth materially more or less than it is today, using the Community page as the home base for those views. Each narrative links its implied outcome to a concrete path for Grifols' growth, profitability and risk profile that you can revisit as new information becomes available.
One of the top community narratives on Grifols: 33% undervalued
"Disciplined cost management, deleveraging efforts, and normalization of business operations are strengthening Grifols' balance sheet and enabling higher free cash flow generation..."
Discover why this Narrative puts Grifols at 33% undervalued .
One last Grifols check that sits beyond the P/E
Before leaning too heavily on where Grifols trades versus peers, it is worth asking who is steering the business and how their rewards line up with your interests. See who runs Grifols and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GRF.MC .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
